Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA interference (RNAi) is a natural mechanism which is present in living cells that selectively "turns off" specific gene's expressions, thereby affecting the production of a specific protein that contributes to disease. Another RNA-targeting technology is antisense technology, where synthetic single-stranded strings of nucleic acids, known as antisense oligonucleotides, bind to RNA and alter/reduce expression of the target RNA. The ranking is based on revenues from 2017, including product sales, collaborations and R&D activity.   

Made with Visme Infographic Maker